Johnson & Johnson
JNJ
NYSE
Pharmaceuticals
$267.37
USD
-6.04 (-2.21%)
At close: Aug 20, 2026, 4:00 PM EDT
Market Cap $629.71B
Volume 6.5M
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. The company is headquartered in New Brunswick, New Jersey and currently employs 138,200 full-time employees. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
CEO
Mr. Joaquin Duato
HQ
New Brunswick, NEW JERSEY, US
Founded
1944
Employees
138,200
Quantli Score
8.4
Outperform
Fin. Health
8.1
Profitability
7.6
Growth
9.0
Cash-Flow Q.
8.8
Key Metrics
7 metrics our research team weighs before forming a view on JNJ.
Based on Quantli research · SEC filings · as of Q2 2026
METRIC
VALUE
CHANGE
TREND (3Y)
Revenue Growth (TTM)
8.1%
+3.4 pp
Gross Margin (TTM)
67.9%
-0.0 pp
Operating Margin (TTM)
26.5%
+2.8 pp
Net Margin (TTM)
21.5%
-3.5 pp
ROE (TTM)
24.8%
-4.1 pp
EPS Growth (TTM)
-7.8%
+30.9 pp
Free Cash Flow (TTM)
$22.23B
+32.6%
Financial Snapshot
Revenue
$97.93B
+8.1%
YoY
Gross Margin
68%
TTM
-0.0%
YoY
Net Income
$21.04B
-7.2%
YoY
Operating Cash Flow
$27.61B
+19.9%
YoY
Key Statistics
Open
$273.40
Previous Close
$273.41
Day Range
$267.37 - $273.40
52 Week Range
$173.33 - $276.47
Volume
6.5M
Average Volume (10 Days)
6.4M
Dividend Yield
2.00%
Valuation Measurement
Market Cap
$629.71B
P/E Ratio (TTM)
29.93
P/S Ratio (TTM)
6.43
Price / Book
7.41
Financial Highlights
Profit Margin
21.5%
Return on Assets
10.5%
Return on Equity
24.8%
Revenue (TTM)
$97.93B
Net Income (TTM)
$21.04B
Diluted EPS (TTM)
$8.62
Total Cash (MRQ)
$20.42B
Levered FCF (TTM)
$22.23B
Latest News
Load more
Turn research into action
Knowing a stock is strong is the start. Knowing how to invest in it when you spot good research is good returns.
Earnings Calendar
Next Earnings
Estimated Q3 Release
Oct 13
Est. EPS
Adjusted consensus estimate
$2.95
Analyst Consensus
Based on 1 analyst ratings
Avg Target: $270.00
(+1.0% upside)
High: $270.00 · Low: $270.00
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%